
News Release

For Immediate Release

11 November 2013

Contact: **Tricia Thompson**
Business Development
+1 (610) 539-3670

PluroGen to Attend MEDICA Conference November 20-23, 2013 Messe Düsseldorf, Germany

(Norristown, Pennsylvania, USA, 4 November 2013) - PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it will attend MEDICA, the world's largest medical trade fair on November 20-23, 2013.

This is the second year in a row that PluroGen will be in attendance. PluroGen representatives will be demonstrating the PluroGel® line of burn and wound care products and looking for new distributors, discussing with them how selling the PluroGel® line will differentiate them to increase their sales and profits.. Kati Weiss, PluroGen's European Manager, will be available throughout the conference for one-on-one meetings at the PluroGen Booth located in Hall 06, Booth G47. To set up a meeting during the show with a PluroGen representative, send an email to europe@plurogen.com.

PluroGen's primary platform is its core PluroGel® surfactant-based biomaterial that is sharply focused to improve outcomes for patients with burns and chronic (non-healing) wounds. PluroGen currently markets 2 exclusive and advantaged medical device barrier products in certain countries in Europe, the Middle East and Africa; PluroGel® Burn and Wound (without antimicrobial) and PluroGel® PSSD (with single antimicrobial for enhanced barrier protection). "PluroGel® is being used in burn and wound centers across Europe with tremendous success." said Neal Koller, President and CEO of PluroGen. "Our team is very excited about attending the MEDICA Congress again this year. Our goal is to find new partners in new countries who have an interest in the extremely high growth sector of the Advanced Wound Care Market, which is estimated to be \$16.8Billion worldwide and growing. We want to educate and update distributors on our exciting new product launch of PluroGel® Burn and Wound as well as continue to tell our story about how our clinically advanced PluroGel® surfactant-based biomaterial can help physicians and healthcare providers make great strides in their burn and wound care challenges. This in turn will help new distributors grow their sales, profits and quality reputation."

About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company's primary platform is its core PluroGel® surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel® are University developed and are in routine use, having shown superior results on more than 14,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration. PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global, commercial and clinical leaders in PluroGen's target markets of burn and wound care. More information can be found at www.plurogen.com. For PluroGen Investor Information, please call +1 (610) 539-3670 or email investorrelations@plurogen.com.

About MEDICA

MEDICA is the world's largest medical trade fair and covers the entire spectrum of exhibits for both ambulant and in-patient treatments. MEDICA will be held at the Messe Düsseldorf in Germany with over 4,500 exhibitors from 70 countries, 17 exhibition halls, 5 exhibition areas, 7 forums and 2 congresses. www.medica-tradefair.com.

Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.